This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
The small molecule universe (SMU) is a collection of more than 1060 synthetically viable organic compounds having a molecular weight of less than 500 Da. Because of the large number of structures, mining the SMU is a difficult but appealing undertaking. Over the previous century, synthetic chemistry has created 60 million molecules. Natural product motifs and diversity-oriented synthesis (DOS) allow for the development of libraries with a wide range of potential structures. Small-molecule drugs are chemical molecules that target key proteins to influence molecular pathways. Because these chemicals have a low molecular weight, they can easily infiltrate cells. Small-molecule medications can be made from natural resources or from leads acquired through rational drug design. Target identification, target validation, hit identification, hit to lead, and lead optimization are all common steps in a target-based drug discovery project.
The procedures used to synthesize chemical substances are referred to as synthetic chemistry methodology. Medicinal chemists play an important role in drug development by selecting and synthesizing molecules that establish structure–activity correlations and demonstrate efficacy and safety in preclinical animal testing.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt